Trial · NCT01514461
Results by group79
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 79
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Fasting Triglycerides From Baseline to 12 Weeks | Placebo | 45.6 | 95% Confidence Interval 6.8 to 98.7 | percent change | |
| Percent Change in Fasting Triglycerides From Baseline to 12 Weeks | LCQ908 20mg | 3.7 | 95% Confidence Interval -24.3 to 42.1 | percent change | |
| Percent Change in Fasting Triglycerides From Baseline to 12 Weeks | LCQ908 40 mg | -13.9 | 95% Confidence Interval -38.9 to 21.3 | percent change | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline or Final Fasting TG < 8.4 mmol/L (750 mg/dL) | Placebo | Week 12 (n = 14, 14, 12) | 14.3 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline or Final Fasting TG < 8.4 mmol/L (750 mg/dL) | LCQ908 20 mg | Week 12 (n = 14, 14, 12) | 21.4 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline or Final Fasting TG < 8.4 mmol/L (750 mg/dL) | LCQ908 40 mg | Week 12 (n = 14, 14, 12) | 50.0 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline or Final Fasting TG < 8.4 mmol/L (750 mg/dL) | Placebo | Week 24 (n = 13, 14, 12) | 30.8 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline or Final Fasting TG < 8.4 mmol/L (750 mg/dL) | LCQ908 20 mg | Week 24 (n = 13, 14, 12) | 35.7 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline or Final Fasting TG < 8.4 mmol/L (750 mg/dL) | LCQ908 40 mg | Week 24 (n = 13, 14, 12) | 33.3 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline or Final Fasting TG < 8.4 mmol/L (750 mg/dL) | Placebo | Week 52 (n = 11, 14, 11) | 18.2 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline or Final Fasting TG < 8.4 mmol/L (750 mg/dL) | LCQ908 20 mg | Week 52 (n = 11, 14, 11) | 21.4 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline or Final Fasting TG < 8.4 mmol/L (750 mg/dL) | LCQ908 40 mg | Week 52 (n = 11, 14, 11) | 27.3 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Final Fasting Triglycerides < 8.4 mmol/L (750 mg/dL) | Placebo | Week 12 (n = 14, 14, 12) | 14.3 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Final Fasting Triglycerides < 8.4 mmol/L (750 mg/dL) | LCQ908 20 mg | Week 12 (n = 14, 14, 12) | 14.3 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Final Fasting Triglycerides < 8.4 mmol/L (750 mg/dL) | LCQ908 40 mg | Week 12 (n = 14, 14, 12) | 33.3 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Final Fasting Triglycerides < 8.4 mmol/L (750 mg/dL) | Placebo | Week 24 (n = 13, 14, 12) | 30.8 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Final Fasting Triglycerides < 8.4 mmol/L (750 mg/dL) | LCQ908 20 mg | Week 24 (n = 13, 14, 12) | 14.3 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Final Fasting Triglycerides < 8.4 mmol/L (750 mg/dL) | LCQ908 40 mg | Week 24 (n = 13, 14, 12) | 16.7 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Final Fasting Triglycerides < 8.4 mmol/L (750 mg/dL) | Placebo | Week 52 (n = 11, 14, 11) | 18.2 | Percentage of participants | |
| Percentage of Patients Responding to Investigational Treatment by Achieving Final Fasting Triglycerides < 8.4 mmol/L (750 mg/dL) | LCQ908 20 mg | Week 52 (n = 11, 14, 11) | 14.3 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01514461/results